← Leaderboards
Susan M Blaney
Baylor College Of Medicine
$10,519,074
Attributed
$11,250,609
Total exposure
100
Grants
70
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $28.5M · FY2005–24$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$54,725,299 · 102
By mechanism
U10$27,580,041 · 1
U01$16,354,541 · 2
K12$4,963,049 · 1
UM1$3,729,283 · 1
M01$1,146,796 · 91
P30$802,668 · 5
Top collaborators
- Peter C Adamson2 shared
- Carl E Allen2 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchFundingResearch PersonnelChildResourcesToxic EffectClinical TrialsUnited States National Institutes Of HealthGrantSourceChildhoodInstitutionTumorDoseComputer Retrieval Of Information On Scientific Projects DatabaseMalignant NeoplasmsDrug KineticsRefractoryResponseHuman SubjectRecurrenceBaseImageGlioma
Grant awards (145)
Pediatric Cancer Program$32,567
P30 · FY2024 · CA · contact PI
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAM$717,393
K12 · FY2023 · CA · contact PI
Pediatric Cancer Program$32,567
P30 · FY2023 · CA · contact PI
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAM$745,678
K12 · FY2022 · CA · contact PI
Pediatric Cancer Program$32,567
P30 · FY2022 · CA · contact PI
Pediatric Oncology Clinical Research Training Program$800,542
K12 · FY2021 · CA · contact PI
Pediatric Cancer Program$40,088
P30 · FY2021 · CA · contact PI
Pediatric Oncology Clinical Research Training Program$923,163
K12 · FY2020 · CA · contact PI
Pediatric Cancer Program$32,567
P30 · FY2020 · CA · contact PI
COG NCTN Network Group Operations Center$23,995,872
U10 · FY2019 · CA
COG NCTN Network Group Operations Center$3,584,169
U10 · FY2019 · CA
Pediatric Oncology Clinical Research Training Program$949,109
K12 · FY2019 · CA · contact PI
Pediatric Oncology Clinical Research Training Program$827,164
K12 · FY2018 · CA · contact PI
DATA SAFETY AND MONITORING BOARD$34,528
P30 · FY2014 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$30,197
P30 · FY2014 · CA · contact PI
DATA SAFETY AND MONITORING BOARD$83,092
P30 · FY2013 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$77,785
P30 · FY2013 · CA · contact PI
Pediatric Phase 1/Pilot Consortium$3,470,000
UM1 · FY2012 · CA · contact PI
DATA SAFETY AND MONITORING BOARD$37,229
P30 · FY2012 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$32,557
P30 · FY2012 · CA · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$3,360,967
U01 · FY2011 · CA · contact PI
CLINICAL TRIAL: A PHASE I TRIAL OF ESCALATING DOSES OF KARENITECIN PLUS CYCLOPH$42,742
M01 · FY2011 · RR · contact PI
DATA SAFETY AND MONITORING BOARD$38,153
P30 · FY2011 · CA · contact PI
CLINICAL TRIAL: A PHASE II TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS$34,826
M01 · FY2011 · RR · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$33,366
P30 · FY2011 · CA · contact PI
CLINICAL TRIAL: PBTC-022 PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTOS$9,103
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: PBTC-019: A PHASE I PHARMACOKINETIC OPTIMAL DOSING STUDY OF INT$9,103
M01 · FY2011 · RR · contact PI
PBTC-025-A PHASE I PHARMACOPKINETIC AND SAFETY STUDY IN CHILDREN$6,332
M01 · FY2011 · RR · contact PI
NANT 2007-02 - A PHASE I STUDY OF BEVACIZUMAB WITH BOLUS$5,144
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF MK-0752 IN PEDIATRIC PATIENTS WITH RECURREN$2,770
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: A PHASE I TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS$2,375
M01 · FY2011 · RR · contact PI
A PHASE I STUDY OF ABT-888, AN ORAL INHIBITOR OF POLY$59
M01 · FY2011 · RR · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$3,476,954
U01 · FY2010 · CA · contact PI
DATA SAFETY AND MONITORING BOARD$42,123
P30 · FY2010 · CA · contact PI
PROTOCOL SPECIFIC RESEARCH SUPPORT$36,838
P30 · FY2010 · CA · contact PI
CLINICAL TRIAL: A PHASE I TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS A$34,717
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: A PHASE I TRIAL OF ESCALATING DOSES OF KARENITECIN PLUS CYCLOPHO$7,631
M01 · FY2010 · RR · contact PI
A STUDY TO DETERMINE THE ACTIVITY OF SCH717454 IN SUBJECTS WITH OSTEOSARCOMA$4,197
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PBTC-019: A PHASE I PHARMACOKINETIC OPTIMAL DOSING STUDY OF INTR$4,197
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PBTC-022 PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTOSA$2,289
M01 · FY2010 · RR · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$2,007,017
U01 · FY2009 · CA · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$1,146,024
U01 · FY2009 · CA · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$750,000
U01 · FY2009 · CA · contact PI
Pediatric Phase 1/Pilot Consortium$259,283
UM1 · FY2009 · CA · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$96,543
U01 · FY2009 · CA · contact PI
Protocol Specific Research$68,359
P30 · FY2009 · CA · contact PI
CLINICAL TRIAL: A PHASE 1 TRIAL OF ESCALATING DOSES OF KARENITECIN PLUS CYCLOPHO$51,548
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE I AND PHARMACOKINETIC STUDY OF ENZASTAURIN$20,441
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PBTC-022 PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTOSA$12,739
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE I TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS A$3,555
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE II TRIAL OF PIRFENIDONE IN CHILDREN, ADOLESCENTS, AND YOUN$593
M01 · FY2009 · RR · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$2,483,710
U01 · FY2008 · CA · contact PI
Protocol Specific Research$59,419
P30 · FY2008 · CA · contact PI
CLINICAL TRIAL: PBTC-022 PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTOSA$19,408
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I/II SAFETY AND EXPLORATORY PHARMACODYNAMIC STUDY OF INT$15,839
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE 1 STUDY OF CC-5013 (LENALIDOMIDE, NSC # 703813, IND # 70$8,700
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE II TRIAL OF 06-BENZYLGUANINE AND TEMOZOLOMIDE IN PEDIATR$8,477
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ADVL0419, A PHASE I STUDY OF VALPROIC ACID IN CHILDREN WITH RECU$7,585
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF SAHA (NSC #701852) IN PEDIATRIC PATIENTS WITH$6,693
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF THE RAF KINASE AND RECEPTOR TYROSINE KINASE I$6,693
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS A$6,246
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I TRIAL OF ESCALATING DOSES OF KARENITECIN PLUS CYCLOPHO$3,793
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF BMS-354825 IN CHILDREN WITH RECURRENT/REFRACT$2,900
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF SUNITINIB (SU11248), AN ORAL MULTI-TARGETED T$2,677
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF VINABLASTINE IN COMBINATION WITH CARBOPLANTIN$2,677
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE II TRIAL OF PIRFENIDONE IN CHILDREN, ADOLESCENTS, AND YOUN$2,231
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ADVL0414, A PHASE I STUDY OF TEMOZOLOMIDE, ORAL IRINOTECAN, AND$1,785
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I CLINICAL TRIAL OF AZD2171 IN CHILDREN WITH RECURRENT O$1,339
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I, MOLECULAR BIOLOGY AND PHASE II STUDY OF LAPATINAB (GW$1,116
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE I/II TRIAL OF R115777 AND XRT IN PEDIATRIC PATIENTS WITH N$446
M01 · FY2008 · RR · contact PI
Children's Oncology Group Phase 1 / Pilot Consortium$2,573,434
U01 · FY2007 · CA · contact PI
Protocol Specific Research$58,666
P30 · FY2007 · CA · contact PI
A PHASE II TRIAL OF 06-BENZYLGUANINE AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS W$30,168
M01 · FY2007 · RR · contact PI
PHASE I/II TRIAL OF R115777 AND XRT IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSE$12,594
M01 · FY2007 · RR · contact PI
A PHASE I TRIAL OF CC-5013 (LENALIDOMIDE) IN PEDIATRIC PATIENTS WITH RECURREN$8,494
M01 · FY2007 · RR · contact PI
ADVL0414, A PHASE I STUDY OF TEMOZOLOMIDE, ORAL IRINOTECAN, AND VINCRISTINE F$7,322
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF CLORETAZINE(TM) (VNP40101M) IN CHILDREN WITH RECURRENT, PROG$3,222
M01 · FY2007 · RR · contact PI
A PHASE I STUDY OF ORAL IRINOTECAN, TEMOZOLOMIDE, AND CEFIXIME IN CHILDREN WI$2,636
M01 · FY2007 · RR · contact PI
PBTC-022 PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTOSAR) IN CHILDRE$2,636
M01 · FY2007 · RR · contact PI
A PHASE I, MOLECULAR BIOLOGY AND PHASE II STUDY OF LAPATINAB (GW572016) IN PE$2,636
M01 · FY2007 · RR · contact PI
A PHASE 1 STUDY OF CC-5013 (LENALIDOMIDE, NSC # 703813, IND # 70116) IN PEDIA$2,343
M01 · FY2007 · RR · contact PI
A PHASE I STUDY OF SAHA (NSC #701852) IN PEDIATRIC PATIENTS WITH RECURRENT OR$2,343
M01 · FY2007 · RR · contact PI
A PHASE I STUDY OF ZD1839 (IRESSA), AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR$1,171
M01 · FY2007 · RR · contact PI
PHASE II TRIAL OF PIRFENIDONE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH$879
M01 · FY2007 · RR · contact PI
ADVL0214, A PHASE I STUDY OF SINGLE AGENT OSI-774 (TARCEVA) FOLLOWED BY OSI-77S$879
M01 · FY2007 · RR · contact PI
PHASE I/II TRIAL OF ZD1839 (IRESSA) IN PEDIATRIC PATIENTS WITH BRAIN STEM TUMORS$586
M01 · FY2007 · RR · contact PI
A PHASE II RANDOMIZED, CROSS-OVER, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL O$301
M01 · FY2007 · RR · contact PI
ADVL0419, A PHASE I STUDY OF VALPROIC ACID IN CHILDREN WITH RECURRENT/PROGRES$293
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF CLORETAZINE(TM) (VNP40101M) IN CHILDREN WITH RECURRENT, PROG$23,263
M01 · FY2006 · RR · contact PI
PHASE I/II TRIAL OF R115777 AND XRT IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSE$18,301
M01 · FY2006 · RR · contact PI
PHASE I STUDY OF CILENGITIDE (EMD 121974) IN CHILDREN WITH REFRATORY BRAIN TUMOR$13,027
M01 · FY2006 · RR · contact PI
ADVL0214, A PHASE I STUDY OF SINGLE AGENT OSI-774 (TARCEVA) FOLLOWED BY OSI-77S$11,476
M01 · FY2006 · RR · contact PI
ADVL0311, A PHASE I STUDY OF PEMETREXED (LY231514, ALIMTA) (NSC #698037, IND$11,476
M01 · FY2006 · RR · contact PI
PHASE I STUDY OF INTRATHECAL GEMCITABINE IN PATIENTS WITH REFRACTORY MALIGNANCY$6,514
M01 · FY2006 · RR · contact PI
PHASE I/II TRIAL OF ZD1839 (IRESSA) IN PEDIATRIC PATIENTS WITH BRAIN STEM TUMORS$4,343
M01 · FY2006 · RR · contact PI
A PHASE I, MOLECULAR BIOLOGY AND PHASE II STUDY OF LAPATINAB (GW572016) IN PE$3,722
M01 · FY2006 · RR · contact PI
A PHASE I TRIAL OF CC-5013 (LENALIDOMIDE) IN PEDIATRIC PATIENTS WITH RECURREN$2,482
M01 · FY2006 · RR · contact PI
PEDIATRIC PHASE I AND PHARMACOKINETIC STUDY OF IRINOTECAN$2,171
M01 · FY2006 · RR · contact PI
A PHASE 1 STUDY OF CC-5013 (LENALIDOMIDE, NSC # 703813, IND # 70116) IN PEDIA$1,551
M01 · FY2006 · RR · contact PI
A PHASE I STUDY OF SAHA (NSC #701852) IN PEDIATRIC PATIENTS WITH RECURRENT OR$1,551
M01 · FY2006 · RR · contact PI
A PHASE II RANDOMIZED, CROSS-OVER, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL O$310
M01 · FY2006 · RR · contact PI
A PHASE I STUDY OF ORAL IRINOTECAN, TEMOZOLOMIDE, AND CEFIXIME IN CHILDREN WI$310
M01 · FY2006 · RR · contact PI
STUDY OF DECITABINE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE$38,042
M01 · FY2005 · RR
PEDIATRIC PHASE I AND PHARMACOKINETIC STUDY OF IRINOTECAN$24,377
M01 · FY2005 · RR
ADVL0214, A PHASE I STUDY OF SINGLE AGENT OSI-774 (TARCEVA) FOLLOWED BY OSI-77S$17,728
M01 · FY2005 · RR
PHASE I TRIAL OF TEMOZOLOMIDE AND O6-BENZYLGUANINE (PBTC-005)$11,449
M01 · FY2005 · RR
PHARMACOKINETICS OF R115777 IN PEDIATRIC PATIENTS WITH REFRACTORY LEUKEMIAS$7,756
M01 · FY2005 · RR
ADVL0212, STUDY OF DEPSIPEPTIDE IN PEDIATRIC REFRACTORY SOLID TUMORS$7,756
M01 · FY2005 · RR
PHASE I STUDY OF INTRATHECAL GEMCITABINE IN PATIENTS WITH REFRACTORY MALIGNANCY$7,017
M01 · FY2005 · RR
ORAL IRINOTECAN, TEMOZOLOMIDE, AND CEFIXIME IN CHILDREN W/ NEUROBLASTOMA$4,063
M01 · FY2005 · RR
PHASE I STUDY OF CILENGITIDE (EMD 121974) IN CHILDREN WITH REFRATORY BRAIN TUMOR$2,955
M01 · FY2005 · RR
PHASE I/II TRIAL OF R115777 AND XRT IN PEDIATRIC PATIENTS W/ GLIOMAS$2,955
M01 · FY2005 · RR
ESCALATING ORAL DOSES OF SCH 66336 IN PEDIATRIC PATIENTS W/ REF BRAIN TUMORS$1,477
M01 · FY2005 · RR
Phase I Trial Of Temozolomide And O6-Benzylguanine (PBTC-005)$49,836
M01 · FY2004 · RR
Pediatric Phase I /Pharmacokinetic Study of Irinotecan$32,798
M01 · FY2004 · RR
ADVL0212, Study Of Depsipeptide In Pediatric Refractory Solid Tumors$23,853
M01 · FY2004 · RR
Phase I/II Trial Of ZD1839 (Iressa) In Pediatric Patients With Brain Stem Tumors$12,353
M01 · FY2004 · RR
Phase I Trial Of G3139 with Cytotoxic Chemotherapy in Childhood Solid Tumors$10,648
M01 · FY2004 · RR
Phase I/II Trial of STI571 in Children with Gliomas$6,389
M01 · FY2004 · RR
Pharmacokinetics of R115777 in Pediatric Refractory Leuk$4,686
M01 · FY2004 · RR
Valacyclovir for Herpes Zoster in Immuncompromi Children$4,259
M01 · FY2004 · RR
Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients$2,981
M01 · FY2004 · RR
Phase I Study Of ZD1839 (Iressa), Oral Epidermal Growth$2,981
M01 · FY2004 · RR
Phase I Study of Intrathecal Spartaject-Busulfan in Children with Neoplastic$852
M01 · FY2004 · RR
Phase II Trial of Phenylbutyrate (NAPB) in Pediatric CNS$852
M01 · FY2004 · RR
Phase I Study of PS-341 in Pediatric Refractory Solid Tu$817
M01 · FY2004 · RR
Pharmacokinetics of Valacyclovir in Pediatric Oncology P$426
M01 · FY2004 · RR
PEDIATRIC BRAIN TUMOR RESEARCH CENTER$128,470
U01 · FY2003 · CA
PEDIATRIC BRAIN TUMOR RESEARCH CENTER$86,742
U01 · FY2002 · CA
PEDIATRIC PHASE I &PHARMACOKINETIC STUDY OF IRINOTECAN$155,764
M01 · FY2001 · RR
PEDIATRIC BRAIN TUMOR RESEARCH CENTER$124,148
U01 · FY2001 · CA
FARNESYLTRANSFERASE DOSAGE IN CHILDREN WHEN ADMINISTERED FOR 21 DAYS$0
M01 · FY2001 · RR
PHASE I TRIAL OF QUINAPRIL IN PEDIATRIC HYPERTENSION$0
M01 · FY2001 · RR
PHENYLBUTYRATE GIVEN IN PEDIATRIC PATIENTS WITH REFACTORY MALIGNANCY$0
M01 · FY2001 · RR
PHASE I STUDY ON INTRATHECAL MAFOSFAMIDE$0
M01 · FY2001 · RR
PHENYLBUTYRATE--PHASE II PEDIATRIC TRIAL FOR CNS TUMORS$148,921
R21 · FY2000 · CA
PEDIATRIC BRAIN TUMOR RESEARCH CENTER$120,532
U01 · FY2000 · CA
POG 9470--PHASE I TRIAL OF CI 980 IN CHILDREN WITH SOLID TUMORS$35,952
M01 · FY2000 · RR
PHASE I STUDY OF SU101 IN PEDIATRIC PATIENTS W/ REFRACTORY MALIGNANCY$35,952
M01 · FY2000 · RR
PHENYLBUTYRATE GIVEN IN PEDIATRIC PATIENTS WITH REFACTORY MALIGNANCY$35,952
M01 · FY2000 · RR
PHASE I STUDY OF INTRATHECAL TOPOTECAN$35,952
M01 · FY2000 · RR
PEDIATRIC PHASE I &PHARMACOKINETIC STUDY OF IRINOTECAN$35,952
M01 · FY2000 · RR
PHASE I TRIAL OF QUINAPRIL IN PEDIATRIC HYPERTENSION$0
M01 · FY2000 · RR
PHASE I STUDY ON INTRATHECAL MAFOSFAMIDE$0
M01 · FY2000 · RR
FARNESYLTRANSFERASE DOSAGE IN CHILDREN WHEN ADMINISTERED FOR 21 DAYS$0
M01 · FY2000 · RR